Compare · NVO vs ZVRA
NVO vs ZVRA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zevra Therapeutics Inc. (ZVRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZVRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 256.3x ZVRA ($714.7M).
- Over the past year, NVO is down 45.3% and ZVRA is up 42.5% - ZVRA leads by 87.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for ZVRA).
- NVO has more recent analyst coverage (25 ratings vs 9 for ZVRA).
- Company
- Novo Nordisk A/S
- Zevra Therapeutics Inc.
- Price
- $41.26+0.62%
- $13.08+8.28%
- Market cap
- $183.15B
- $714.7M
- 1M return
- -10.46%
- +17.54%
- 1Y return
- -45.32%
- +42.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 4
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest ZVRA
- Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
- Zevra Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by SVP, Finance & Corp Controller Sangiovanni Timothy J.
- Chief Legal & Compliance Thompson Rahsaan sold $20,272 worth of shares (1,794 units at $11.30) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 48,125 units (SEC Form 4)
- Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
- SEC Form 144 filed by Zevra Therapeutics Inc.
- SEC Form 10-Q filed by Zevra Therapeutics Inc.
- Zevra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zevra Reports First Quarter 2026 Financial Results and Corporate Update